Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy ( GO )
Status:
Completed
Trial end date:
2020-05-21
Target enrollment:
Participant gender:
Summary
The purpose of the current study is to confirm safety/tolerability and key pharmacodynamic
(PD) effects that are considered to drive clinical benefit in GO patients.